LS is diagnosed using clinical criteria like the Amsterdam Criteria II and Revised Bethesda Guidelines, tumor testing for MSI and immunohistochemistry to detect MMR protein deficiencies, and genetic testing of peripheral blood DNA to identify germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2, EPCAM). This evidence concerns the gene MLH1 and Leigh syndrome.